RET proto-oncogene genotyping using unlabeled probes, the masking technique, and amplicon high-resolution melting analysis

被引:18
作者
Margraf, Rebecca L.
Mao, Rong
Highsmith, W. Edward
Holtegaard, Leonard M.
Wittwer, Carl T.
机构
[1] ARUP Inst Clin & Expt Pathol, Adv Technol Grp, Salt Lake City, UT 84108 USA
[2] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84112 USA
[3] Mayo Clin, Genet Mol Lab, Rochester, MN USA
关键词
D O I
10.2353/jmoldx.2007.060091
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Single bp mutations in the RET proto-oncogene can cause multiple endocrine neoplasia type 2 syndromes. The conventional approach for genotyping RET mutations is sequencing the exons. A closed-tube RET genotyping assay using a saturating DNA dye, unlabeled probes, and amplicon high-resolution melting analysis was developed. The method required two sequential polymerase chain reaction stages, a primary and secondary assay. The primary assay analyzed RET exons 10, 11, 13, 14, and 16 with a total of seven reactions using eight unlabeled probes. The primary assay genotyped wild-type exons, a common exon 13 polymorphism, and an exon 16 mutation, whereas other RET sequence variation was detected. The primary unlabeled probe data limited the possible genotypes for the detected RET sequence variation, which permitted genotyping in a secondary assay with only two to five reactions. Six probes were designed with the masking technique and masked selected sequence variations to allow unambiguous analysis of other mutations elsewhere under the probe. After this two-stage RET genotyping assay, less than 0.2% of exons tested would require sequencig for genotype. A blinded study generated from five wild type and 29 available RET sequence variation samples was 100% concordant with sequencing. Amplicon high-resolution melting analysis with unlabeled probes and the masking technique is a fast, accurate method for genotyping the > 50 RET sequence variations.
引用
收藏
页码:184 / 196
页数:13
相关论文
共 41 条
[1]   Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases [J].
Ahmed, SA ;
Snow-Bailey, K ;
Highsmith, WE ;
Sun, WM ;
Fenwick, RG ;
Mao, R .
JOURNAL OF MOLECULAR DIAGNOSTICS, 2005, 7 (02) :283-288
[2]   Polymorphisms in Exon 13 and intron 14 of the RET protooncogene:: Genetic modifiers of medullary thyroid carcinoma? [J].
Baumgartner-Parzer, SM ;
Lang, R ;
Wagner, L ;
Heinze, G ;
Niederle, B ;
Kaserer, K ;
Waldhäusl, W ;
Vierhapper, H .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (11) :6232-6236
[3]   A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A [J].
Berndt, I ;
Reuter, M ;
Saller, B ;
Frank-Raue, K ;
Groth, P ;
Grussendorf, M ;
Raue, F ;
Ritter, MM ;
Höppner, W .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (03) :770-774
[4]  
Blank RD, 1996, CLIN CHEM, V42, P598
[5]   Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression [J].
Borrego, S ;
Sáez, ME ;
Ruiz, A ;
Gimm, O ;
López-Alonso, M ;
Antiñolo, G ;
Eng, C .
JOURNAL OF MEDICAL GENETICS, 1999, 36 (10) :771-774
[6]  
CECCHERINI I, 1994, ONCOGENE, V9, P3025
[7]  
de la Fuente M, 2001, CLIN CHEM, V47, P1131
[8]  
Demeester R, 2001, Hum Mutat, V17, P354, DOI 10.1002/humu.42
[9]   Exon 5 of the RET proto-oncogene:: A newly detected risk exon for familial medullary thyroid carcinoma, a novel germ-line mutation Gly321 Arg [J].
Dvorakova, S ;
Vaclavikova, E ;
Duskova, J ;
Vlcek, P ;
Ryska, A ;
Bendlova, B .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2005, 28 (10) :905-909
[10]   RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population [J].
Elisei, R ;
Cosci, B ;
Romei, C ;
Bottici, V ;
Sculli, M ;
Lari, R ;
Barale, R ;
Pacini, F ;
Pinchera, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (07) :3579-3584